Catalyst Pharmaceuticals, Inc. provided earnings guidance for the year 2022. For the year, total revenues will be in the range of between $195 million and $205 million, representing a 38% - 45% increase in total revenues compared to 2021.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.81 USD | -2.04% | -3.17% | -5.53% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.53% | 1.91B | |
-1.62% | 89.22B | |
+1.32% | 40.49B | |
-15.57% | 32.79B | |
+64.13% | 26.23B | |
-21.55% | 14.52B | |
-7.72% | 13.09B | |
-44.07% | 11.6B | |
-13.06% | 11.5B | |
+4.94% | 8.82B |
- Stock Market
- Equities
- CPRX Stock
- News Catalyst Pharmaceuticals, Inc.
- Catalyst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022